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ABSTRACT: Ketoreductase enzymes (KRs) with a high degree of regio- and stereoselectivity are useful biocatalysts for the pro-
duction of small, specific chiral alcohols from achiral ketones. Actinorhodin KR (actKR), part of a type II polyketide synthase in-
volved in the biosynthesis of the antibiotic actinorhodin, can also turn over small ketones. In vitro studies assessing stereocontrol in 
actKR have found that, in the “reverse” direction, the wild-type (WT) enzyme’s mild preference for S-α-tetralol is enhanced by 
certain mutations (e.g. P94L); and entirely reversed by others (e.g. V151L) in favor of R-α-tetralol. Here, we employ computation-
ally cost-effective atomistic simulations to rationalize these trends in WT, P94L, and V151L actKR, using trans-1-decalone (1) as 
the model substrate. Three potential factors (FI-FIII) are investigated: frequency of pro-R vs. pro-S reactive poses (FI) is assessed 
with classical molecular dynamics (MD); binding affinity of pro-R vs. pro-S orientations (FII) is compared using the binding free 
energy method MM/PBSA; and differences in reaction barriers towards trans-1-decalol (FIII) are assessed by hybrid semiempirical 
quantum / classical (QM/MM) MD simulations with umbrella sampling, benchmarked with density functional theory. No single 
factor is found to dominate stereocontrol: FI largely determines the selectivity of V151L actKR, whereas FIII is more dominant in 
the case of P94L. It is also found that formation of S-trans-1-decalol or R-trans-1-decalol mainly arises from the reduction of the 
trans-1-decalone enantiomers (4aS,8aR)-1 or (4aR,8aS)-1, respectively. Our work highlights the complexity of enzyme stereoselec-
tivity as well as the usefulness of atomistic simulations to aid the design of stereoselective biocatalysts. 
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1. Introduction 
Typically found in actinomycete bacteria, type II polyketide 
synthases (PKSs) are large multienzyme complexes consisting 
of multiple standalone units.1-3  In a perfect example of enzy-
matic teamwork, each of these PKS domains is highly special-
ized in catalyzing a particular biosynthetic step, first “grow-
ing” a reactive polyketide chain, and then processing it into a 
variety of natural products: these include anticancer agents 
(e.g. daunorubicin and doxorubicin), and antibiotics (e.g. ac-
tinorhodin, tetracycline, and doxycycline).1-2  
A key component of PKSs is their ketoreductase (KR) do-
main,4-7 which typically exhibits some degree of regio- and 
stereoselectivity in catalyzing the reduction of polyketide 
chains. Together with several other KRs unrelated to PKSs, 
these enzymes have emerged as promising commercial biocat-
alysts8-10 for the manufacture of small chiral alcohols from 
achiral ketones; and even for the synthesis of “unnatural natu-
ral products” with potentially improved antibiotic properties.2  
Such rise to prominence was significantly aided by the advent 
of novel protein reengineering techniques,11-12 which have 
revolutionized biocatalysis by speeding up the design and 
screening of evolved KR mutants.9-10 
Actinorhodin KR (actKR) from Streptomyces coelicolor has 
been attracting interest as a potential biocatalyst since at least 
the mid-2000s.5, 13-14  Examination of its sequence and crystal 
structures5, 13-14 confirmed the enzyme’s homotetrameric nature 
(Figure 1a), and its structural and mechanistic similarity with 
enzymes of the short-chain dehydrogenase/reductase (SDR) 
family, especially fatty acid synthases (FASs). Essential for its 
activity are the presence in each active site of the NADPH 
cofactor, and of the catalytic tetrad Asn114-Ser144-Tyr157-
Lys161 (Figure 1b).13 
Another salient structural element is the flexible α6-α7 loop 
(Figure 1c and d), which varies substantially in size and com-
position across SDRs, and was proposed to play some role in 
the stereocontrol and activity of Lactobacillus kefir short-
chain alcohol dehydrogenase.10 Conformational variation of 
actKR’s α6-α7 loop between “open” and “closed” is evident 
when superimposing monomers A and B of the wild-type 
actKR crystal structure (PDB: 2RH4; Figure 1d).14 
The catalytic cycle of actKR begins when a ketone or 
polyketide substrate binds to its active site so that the oxygen 
of the carbonyl to be reduced is sandwiched between the cata-
lytic Ser144 and Tyr157, with whose hydroxyl groups it forms 
hydrogen bonds (Figure 1b). Reduction then kicks off 
(Scheme 1; Figure 1b) when a hydride (H–) from NADPH 
transfers to the carbonyl carbon, yielding the oxidized form 
NADP+; concertedly (but asynchronously) with respect to the 
hydride transfer, the carbonyl oxygen abstracts a proton from 
Tyr157 (to which it remains hydrogen-bonded). The deproto-
nated Tyr157 is further stabilized by retaining its hydrogen 
bond to one of the cofactor’s ribose hydroxyl groups (and is 
reprotonated in subsequent steps via H+ transfers from the 
ribose and Lys161).15 During this fundamental mechanistic 
step, which was shown to be rate-limiting in a human ketoacyl 
reductase,15 the substrate’s orientation with respect to the 
plane of NADPH’s nicotinamide moiety determines whether 
the H– attacks in a pro-R or pro-S fashion (Scheme 1 top vs. 
bottom), and thus ultimately dictates the stereochemical out-
come of the reaction (R- or S- alcohol). 
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Figure 1.  Structural features of wild-type actinorhodin ketoreductase (based on PDB ID 2RH4).14 (a) Overall assembly of the four mono-
mers A-D (grey: A, C; red: B, D) showing: the catalytic tetrad N114-S144-Y157-K161 in A (green sticks); and the NADPH cofactor in A-
D (yellow spheres and sticks). H atoms omitted for clarity. (b) Closeup of the active site of monomer A, showing NADPH (C atoms in 
yellow); labelled tetrad residues (C in green); and a ketone fragment (C in magenta) docked in reactive position. O, N, P are rendered in 
red, blue, and orange, respectively. H atoms omitted for clarity, except for: hydroxyl H atoms on S144, Y157, NADPH ribose (grey 
spheres); and the reductive H– (black). Relevant hydrogen bonds are shown in magenta; black line denotes direction of reductive H– trans-
fer. (c)  Side view of actKR as shown in (a), highlighting the α6-α7 loop in monomers A-D (A, C, open: light blue; B, D, closed: pink).  
(d)  Monomer B superimposed onto monomer A.   
Scheme 1.  Rate-limiting step of actKR (reductive hydride transfer) and its stereochemistry.a,b 
 
a Ketone substrate orientation (left) determines whether H– attack is pro-R or pro-S, and accordingly gives rise to an R- or S- product 
(right).  b Magenta lines denote hydrogen bonds. 
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In nature, the enzyme typically forms a complex with an 
acyl carrier protein (ACP) bearing a 16-carbon polyketide 
chain (octaketide; cf. Chart 1 top), which is then unsheathed 
into one of the active sites, likely cyclized between the C7 and 
C12 positions and reduced specifically at the C9 position14, 16-
17 before further processing by other PKS modules.   
In vitro, wild-type (WT) actKR and 29 strategically chosen 
mutants were extensively examined by Korman, Javidpour, et 
al.,14, 16-17 looking for improved stereocontrol in the turnover of 
model ketone and alcohol substrates (i.e. in the “forwards” and 
“reverse” directions, respectively). More specifically, to study 
the “forwards” reduction reaction, the authors’ preferred sub-
strate is trans-1-decalone (1; Chart 1, left),14, 16-17 since other 
potential candidates, notably the part-aromatic α-tetralone, 
were found to be turned over very sluggishly.14 Rather than 
employing 1’s directly corresponding alcohol trans-1-decalol 
(2) with its four possible stereoisomers (Chart 1, center), the 
authors assess the “reverse” oxidation reaction using the dia-
stereomeric pair R-α-tetralol / S-α-tetralol (R-3 / S-3; Chart 1, 
right),14, 16-17 both of which are readily available commercially 
(in contrast to stereoisomers of 2). 
Assuming that the selectivity of the “forwards” and “re-
verse” reactions are still directly comparable microscopically 
(despite the slight change in substrates), two of the 29 mutants 
demonstrate particularly high stereoselectivity (as per data in 
Table 1): P94L has exclusive specificity for S-3; and V151L, 
has exclusive specificity for R-3. By comparison, WT actKR 
only has a very mild preference for S-3 over R-3 (3.5:1). 
Table 1. In vitro specificity constants of key actKR variants 
towards reduction of 1 and oxidation of 3. 
Variant kcat/KM (1)a,b kcat/KM (R-3)a kcat/KM (S-3)a 
WTc,d 3.23 ± 0.32 0.010 ± 0.001 0.035± 0.006 
V151Le 1.28 ± 0.18 0.026 ± 0.005 inhibition 
P94Ld 1.02 ± 0.59 inhibition 0.036 ± 0.011 
a s–1 mM–1. b Racemate: (4aS,8aR)-1 and (4aR,8aS)-1 (cf. 
text). c Reference 14. d Reference 16. e Reference 17. 
The “forwards” reaction is further complicated by the fact 
that 1 (e.g. as purchased from Sigma Aldrich) exists as a race-
mate of the enantiomers (4aS,8aR)-1 and (4aR,8aS)-1 (hence-
forth SR-1 and RS-1, and with dark vs. light blue color codes, 
respectively, in Chart 1 and subsequent figures). Consequent-
ly, reduction of 1 can yield four different stereoisomers of 2 
(Chart 1, center): when attacked by H– in pro-R orientation, 
SR-1 can only yield (1R,4aS,8aR)-2 (henceforth RSR-2; black 
in Chart 1), and RS-1 can only yield (1R,4aR,8aS)-2 (RRS-2; 
grey); conversely, when attacked in pro-S orientation, SR-1 
and RS-1 can only yield (1S,4aS,8aR)-2 and (1S,4aR,8aS)-2, 
respectively (SSR-2 and SRS-2; red and orange in Chart 1).  
Thus, when simulating the enzymatic reaction to study its ste-
reoselectivity in the “forwards” direction, all four outcomes 
need to be considered. For illustration, putative Michaelis 
complexes in WT actKR for these scenarios are shown in Fig-
ure 2.  
Due to increases in computer speed and improvements in 
algorithms, parameters, and usability over the past decades,18 
in silico biomolecular simulation is increasingly used to com-
plement experimental enzymatic studies,19-21 including those 
focusing on the design of novel enzyme variants relevant for 
biocatalysis.22-25 Indeed, enzyme reactivity and stereocontrol 
are often the result of a subtle interplay between different fac-
tors that are difficult to examine separately experimentally.26 
In short, enzyme variants conferring stereoselectivity can ei-
ther do so by favoring formation of a particular reactive com-
plex; or by favoring efficient reaction of the stereochemistry-
determining step (or subsequent steps); or a combination of 
both. Here, we assess the stereoselectivity of actKR variants 
using three different factors that can easily be assessed indi-
vidually through simulation. 
Factor I (henceforth FI) is the likelihood of the enzyme-
substrate complex attaining a “reactive” pose (or Michaelis 
complex); or, in other words, how likely it is for the substrate 
to reach an orientation and conformation at which key intera-
tomic distances are sufficiently close for a reaction to occur.  
Any imbalance of this factor in favor of reactive pro-R or pro-
S orientations will thus affect an enzyme’s stereocontrol by 
giving a head start to one reaction pathway over the other. In 
principle, F1 describes the energetics of reaching and main-
taining a reactive pose.27 This incorporates the interplay be-
tween conformational fluctuations in the enzyme and substrate 
(‘dynamics’), and may even be affected by mutations far from 
the active site.26 Computationally, this can be probed by clas-
sical molecular dynamics (MD) simulations; in some cases 
(e.g. with sufficient structural information and particular 
prochiral binding orientations precluded), molecular docking 
may suffice.28-29 
Factor II (henceforth FII) can be seen as part of FI, but fo-
cusing solely on the end point, i.e. the binding affinity (or 
binding free energy; ΔGbind) of a specific substrate in its reac-
tive pose within an enzyme’s active site. Assuming that reac-
tive poses can be attained by both prochiral orientations, one 
prochiral orientation may be preferred over the other (i.e. 
ΔΔGbind ≠ 0), thereby favoring formation of the product asso-
ciated with the preferred prochirality. In silico methods for 
calculating ΔGbind include (but are by no means limited to) 
WaterSwap,30 enhanced Monte Carlo,31 and MM/PBSA.32-35 
Finally, Factor III (henceforth FIII) is the height of the free 
energy barrier separating reactants and products of different 
chirality: if a substrate in a reactive pro-R or pro-S orientation 
is closer in energy to the corresponding transition state, then 
the associated product will be more accessible than its coun-
terpart. A range of computational approaches are available to 
determine such barriers in enzyme reactions;36-38 a popular 
option is the use of a hybrid quantum / classical (QM/MM) 
approach,39 where the computationally costly QM treatment 
can be limited to regions of chemical change (without time-
intensive parameterization).37-39   
In the present work, we describe our computational efforts 
to rationalize the stereoselectivity of WT, P94L, and V151L 
actKR towards 1, determining the role of FI-FIII in each case. 
Based on the assumption that the stereospecific oxidation of 3 
is comparable to the stereoselective reduction of 1, we expect 
P94L actKR to preferentially form (1S)-trans-1-decalol; 
V151L actKR to preferentially form (1R)-trans-1-decalol; and 
a slight preference for (1S)-trans-1-decalol by WT actKR. 
Focusing on a potential biocatalyst that has thus far been little 
studied in silico, we aim to show that physically realistic but 
relatively inexpensive computational simulations can be readi-
ly employed in this and similar contexts, to explain the behav-
ior of other promising biocatalysts, and helping to direct the 
design of novel mutants with enhanced stereocontrol. 
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Chart 1.  actKR substrates discussed in this work.a,b 
 
a 1 and 2 color-coded as in Figure 4 and Figure 6, respectively.  b Underlined R or S labels in 2 and 3 (and throughout the text) mark stere-
ocenters introduced/removed by actKR.  c C7-C12 cyclisation prior to reduction at C9.  d [S] denotes link to ACP (see text). 
 
Figure 2.  Comparison of (a, b) pro-R and pro-S poses of SR-1 in WT actKR; and (c, d) as before, but with RS-1. In the top left of each 
panel, we indicate the enantiomer of 2 generated in each case (cf. Chart 1). Snapshots are taken from the opposite angle to that in Figure 




2. Computational Strategy and Details 
General Procedure. For FI, FII, and FIII investigations 
alike, the first step entails running a number of independent 
classical MD simulations, to sample conformational space at 
relatively low computational cost. 
In MD simulations for FI, which we henceforth refer to as 
“free”, the substrate is left free to explore as many orientations 
as possible in the binding site: the frequency of reactive pro-R 
and pro-S poses may be directly extracted from these runs. To 
avoid substrate diffusion from the active site, a one-sided har-
monic restraint (k = 50 kcal mol–1 Å–2) is employed when the 
center of mass of the substrate moves farther than 8 Å from 
the center of mass of NADPH’s nicotinamide moiety. 
To provide starting points for evaluating FII and FIII, MD 
simulations were also performed of the “Michaelis” or “reac-
tive” pro-R and pro-S enzyme-substrate complexes, from 
which, in principle, the chemical reaction can readily begin. 
These “restrained” MD simulations include one-sided harmon-
ic restraints on three key interatomic distances, and an addi-
tional dihedral angle restraint to prevent the substrate from 
‘flipping’ between pro-R and pro-S (see Supporting Infor-
mation for further details). 
To determine the role of FII, ΔGbind of SR-1 and RS-1 in 
their two prochiral orientations is calculated through a series 
of MM/PBSA calculations32-35 (vide infra) on the resulting 
“restrained” trajectories. Probing the role of FIII requires ade-
quate sampling of free energy barriers for the conversion of 
1’s two enantiomers to one of the four accessible stereoiso-
mers of 2. To do this, we select a total of 120 representative 
snapshots from the “restrained” MD simulations and carry out, 
on each snapshot, hybrid quantum/classical MD (QM/MM 
MD) with umbrella sampling (US) along a reaction coordinate 
(vide infra).38  
For simplicity, all classical and QM/MM MD simulations 
are run in two distinct sets, treating enantiomers SR-1 and RS-
1 as separate substrates and, thus, with only one or the other 
enantiomer occupying all four active sites in each set. 
Starting Structures.  Six starting structures [actKR-
(NADPH)4-14] are set up with all four sites occupied: SR-1 or 
RS-1 in WT, P94L, or V151L actKR. All starting structures 
are constructed from our reference WT crystal structure (PDB 
ID: 2RH4),14 to demonstrate the possibility of assessing en-
zyme variants for which no crystal structure has been ob-
tained. Existing mutant crystal structures (V151L; PDB ID: 
4DBZ17 and P94L; PDB IDs: 3RI3, 3QRW)16 are checked to 
ensure that constructed mutants retain plausibly oriented 
sidechains. Constructed structures are henceforth labelled as 
follows: WT-SR-14 (cf. Figure 2a and 2b), V151L-SR-14, and 
P94L-SR-14 for one enantiomer of 1; and WT-RS-14 (cf. Figure 
2c and 2d), V151L-RS-14, and P94L-RS-14 for the other. 
In all six cases, active sites in monomers A and B are popu-
lated with the substrate in pro-R orientation whereas those in 
monomers C and D are populated with the substrate in pro-S 
orientation. All four monomers are modelled from residues 1 
to 261. All residues are modelled in their standard protonation 
states, in line with pKas predicted by PROPKA 3.1.
40 Hydro-
gens are added with AmberTools’ (version 17)41 reduce utility, 
resulting in His162 being singly protonated on Nδ1; His153 
and His201 on Nε2. Using tleap,41 standard N- and C-termini 
are introduced and the structure is solvated in a truncated oc-
tahedral box of water extending at least 11 Å from any protein 
atom, with 40 Na+ ions added to neutralize the system. Start-
ing structure files and further details regarding starting struc-
ture generation are available as Supporting Information. 
Classical MD. MD simulations of our six actKR-
(NADPH)4-14 systems in explicit water are run with the 
AMBER software package (version 16, 2017 distribution),41-42 
taking advantage of GPU acceleration where applicable.43  
Postprocessing and analysis of MD trajectories are carried out 
with the CPPTRAJ utility;44 and visual inspection is conducted 
with VMD.45 The protein and ions are described by the ff14SB 
forcefield,46 the NADPH cofactor by the forcefield from 
Holmberg and coworkers,47 and water using the TIP3P 
model.48 The GAFF forcefield49 with AM1-BCC charges de-
rived by antechamber50-51 is used for SR-1 and RS-1 (see also 
Supporting Information). The default cutoff of 8 Å is used to 
compute Lennard-Jones and Coulomb interactions, with Cou-
lomb interactions beyond this limit computed using the Parti-
cle Mesh Ewald method.52-53   
For both the “free” and “restrained” MD simulations (vide 
supra) we carry out eight independent simulations (different 
random seeds) for each of the six actKR-(NADPH)4-14 start-
ing structures. This results in a total of 8 × 6 = 48 MD runs for 
both the “free” and “restrained” sets (96 in total). Each of the 
MD runs is carried out with the following general procedure 
(restraints retained throughout): minimization (600 steps); 
solvent equilibration (9 ps, NVT); heating (20 ps, NVT); equi-
libration (2040 ps, NpT); and production (12 ns, NpT). Produc-
tion runs are conducted in the NpT ensemble with a time-step 
of 2 fs. A constant pressure of 1 atm is enforced via the Ber-
endsen barostat54 and a constant temperature of 298 K is en-
forced via the Langevin thermostat55 (collision frequency set at 
5 ps−1). Bonds containing hydrogen are constrained by em-
ploying the SETTLE and SHAKE algorithms.56 (See Support-
ing Information for details on settings in the pre-production 
stages). 
MM/PBSA Calculations. MM/PBSA calculations32-35 are 
run on 500 snapshots from each restrained MD trajectory, on 
16 processors, using AmberTools’ MMPBSA.py.MPI utility,57 
with default atomic radii,58 settings, and parameters.42, 57 The 
only exceptions are the ionic strength, which is set at 0.025 
mol dm−3 to reflect the 40 Na+ ions originally present in the 
simulations; and the internal dielectric constant εint, which is 
set to 4.0 as advised by Wang and coworkers.35 The six 
actKR-(NADPH)4-14 topologies are preprocessed using the 
ante-MMPBSA.py tool.57 
The eight trajectories of each of the six actKR-(NADPH)4-
14 systems are parsed by MMPBSA.py.MPI as six individual 
96 ns “supertrajectories”, and each MM/PBSA calculation 
then runs on snapshots taken every 24 ps.  Since each system 
contains four instances of 1 (i.e. one in each active site), four 
separate MM/PBSA runs are required on each “supertrajecto-
ry” (i.e. 24 in total, giving 24 ΔGbind values).  Entropic correc-
tions to these values are calculated using the interaction entro-
py method reported by Duan et al.59 
QM/MM MD with Umbrella Sampling. All QM/MM MD 
simulations are run with AMBER’s sander MD engine.60-61  
Apart from the time-step (here 1 fs) and the absence of re-
straints other than the reaction coordinate, all other conditions 
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are identical to the classical MD production runs. The QM 
region (with explicit treatment of electrons) comprises: the 
reacting substrate in its entirety; NADPH’s nicotinamide moi-
ety up to the first ribose; the Ser144 and Tyr157 sidechains 
(from Cβ); and three hydrogen link-atoms at the QM-MM 
boundary (Figure 3). All remaining atoms are included in the 
classical (MM) region. The SHAKE algorithm is switched off 
in the QM region, and atoms are treated using the semiempiri-
cal method PM6.62 PM6 was chosen over other semiempirical 
methods after benchmarking the reaction on a small model 
with higher-level QM calculations (SCS-MP263-64 single-point 
energy calculations on B3LYP65/6-31+G(d,p)-optimized po-
tential energy surfaces); PM6 correctly identified the mecha-
nism with a highly similar transition state, even though it sig-
nificantly overestimates the barrier for reaction and the reac-
tion energy. Details of benchmarking calculations are provided 
as Supporting Information; relevant coordinates and frequency 
calculations are also available66 for all stationary points in the 
ioChem-BD repository.67 
 
Figure 3.  QM region for QM/MM MD US simulations (rendered 
as sticks, except for three capping H atoms rendered as white 
spheres). Key: white: H; grey: C; blue: N; red: O. Secondary 
structure of MM region rendered as yellow ribbon. The chosen 
reaction coordinate (x – y) is marked with blue and black lines; 
atoms included in it are defined in the text. 
Simulations are started from a series of representative reac-
tive snapshots (see Supporting Information) from the re-
strained MD simulations, with retention of atom velocities. 
Ten such snapshots are chosen for each of the twelve reaction 
paths to be compared: reduction of SR-1 to either (1) RSR-2 or 
(2) SSR-2; and reduction of RS-1 to either (3) RRS-2 or (4) 
SRS-2; in WT; (5-8) P94L; and (9-12) V151L actKR. Only 
one of the four substrates present in each snapshot is consid-
ered for umbrella sampling (US).  
Hydride transfer (i.e. the reaction coordinate) is monitored 
using the difference between two key distances (Figure 3): the 
distance NADPH:H−–1:C1 (y) is subtracted from the distance 
NADPH:H−–NADPH:CH− (x). Umbrella sampling (US) is 
performed by lengthening a restraint on the reaction coordi-
nate (x – y) in 0.1 Å steps (“windows”) starting from a value 
close to that found in the initial snapshot, and thus gradually 
“forcing” the system to react until (x – y) reaches a value of 
1.8 Å. Each US window is simulated with QM/MM MD for 2 
ps, and (x – y) is restrained at the desired length through a 
harmonic biasing potential (k = 100 kcal mol−1 Å−2): the last 
configuration of each US window is used to start the QM/MM 
MD simulation for the following one. Depending on the start-
ing value of (x – y), the simulation time for each individual 
US simulation ranges from 66 ps (33 windows) to 90 ps (45 
windows), with the total cumulative simulation time for each 
free energy profile ranging from 728 ps to 840 ps. The poten-
tial of mean force (PMF) along (x – y) amounts to the free 
energy profile of the reduction, and was obtained from the US 
runs using the weighted histogram analysis method 
(WHAM)68-69 with the eponymous program by Grossfield:70 
this also carries out error analysis through Monte-Carlo boot-
strapping. PMFs are extracted both individually for all 120 US 
runs, and cumulatively for the 12 processes sampled. A num-
ber of runs were discarded as outliers, for example when they 
did not manage to capture the concerted proton abstraction as 
observed in our benchmarking studies; all discarded runs were 
replaced. Details regarding reruns, WHAM, and error analysis 
are given in the Supporting Information. 
 
3. Results and Discussion 
In the subsections below, we first discuss findings from our 
calculations regarding the individual effects of FI-FIII on 
actKR stereoselectivity upon reduction of 1 to 2. We then 
examine which combinations of factors come into play when 
determining stereocontrol in WT, P94L, and V151L actKR, 
drawing comparisons with corresponding in vitro observations 
on the oxidation of 3,14, 16-17 and including trends between en-
antiomers of 1. Finally, we discuss our protocols and their 
potential for high-throughput screening, focusing on the simu-
lation lengths required to achieve appreciable accuracy.  
Formation of Reactive Complexes: FI. We measure the 
difference (Δ) between the frequency of reactive pro-R and 
reactive pro-S poses of SR-1 (Δ[pro-R – pro-S]SR-1) and RS-1 (Δ[pro-
R – pro-S]RS-1) in WT, P94L, and V151L actKR as they occur in 
our “free” MD simulations. Criteria to determine whether or 
not a pose is “reactive”, and whether its prochirality is pro-R 
or pro-S, are based on the restraints imposed on “restrained” 
MD simulations used to study FII and FIII (Supporting In-
formation, Table S1).  
For each of our six simulated systems (WT-SR-14, V151L-
SR-14, P94L-SR-14, WT-RS-14, V151L-RS-14, and P94L-RS-
14), statistics for Δ[pro-R – pro-S]SR-1 or Δ[pro-R – pro-S]RS-1 are 
measured cumulatively: in other words, the 8 MD replicas 
conducted for each of the six systems are considered collec-
tively, as are all 4 active sites. Δ[pro-R – pro-S]SR-1 and Δ[pro-R – pro-
S]RS-1 are calculated for each variant using: 
Δ[pro-R −pro-S]SR-1 = (
reactive pro-R SR-1 poses
96000
−
reactive pro-S SR-1 poses
96000
) × 100  
and 
Δ[pro-R −pro-S]RS-1 = (
reactive pro-R RS-1 poses
96000
−
reactive pro-S RS-1 poses
96000
) × 100 ; 
where the denominator 96000 reflects the fact that each of 
the eight replicas we are dealing with has 3000 frames (250 
per ns), and that each of these frames has 4 active sites (and 4 
instances of 1).  A general Δ for trans-1-decalone as a whole 
(Δ[pro-R – pro-S]1) is then obtained by summing Δ[pro-R – pro-S]SR-1 
and Δ[pro-R – pro-S]RS-1. 
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Figure 4. Difference (Δ) between the frequency of reactive pro-R 
and reactive pro-S poses in “free” MD simulations of: (dark blue) 
SR-1; (light blue) RS-1; and (brown) 1 overall, within P94L, 
V151L, and WT actKR. Negative values indicate excess of pro-S 
reactive poses (red points), positive values excess of pro-R poses 
(black point). See also color codes in Chart 1; lines are to guide 
the eye. Errors indicated are based on leave-one-out procedure 
(details in Supporting Information). 
Although the overall frequency of pro-R and pro-S reactive 
poses is generally low (the highest being 8.3% across the 8 
V151L-RS-14 MD replicas), significant trends still emerge 
(Figure 4). The first observation to make is that, regardless of 
actKR variant, simulations with SR-1 (dark blue) consistently 
show an excess of reactive pro-S poses (most marked in WT-
SR-14 at 5.1%), whereas RS-1 systems (light blue) all favor 
reactive pro-R poses instead (most markedly in V151L-RS-14 
at 7.5%). 
A second noteworthy observation is that for the overall dif-
ference in pro-R / pro-S reactive poses (Δ[pro-R – pro-S]1; brown 
line in Figure 4), V151L actKR has an excess of reactive pro-
R poses (3.9%; black diamond in Figure 4), whereas both WT 
and P94L actKR have an excess of reactive pro-S poses (red 
diamonds). 
The excess of reactive pro-R poses seen in V151L actKR is 
encouragingly in line with the mutant’s observed in vitro spec-
ificity towards R-3 over S-3 in the reverse direction.17 Similar-
ly, the slight excess of pro-S reactive poses emerging from 
simulations of P94L and WT actKR is in line with in vitro 
observations that both are preferentially turning over S-3.16 
Nonetheless, if FI were the predominant factor driving P94L 
actKR’s exclusive preference for S-3, one would expect a far 
greater excess of reactive pro-S poses to emerge.  
Binding Free Energy of Reactive Poses: FII. The role of 
FII was investigated through separate MM/PBSA binding free 
energy calculations on each of the four active sites of our six 
actKR-(NADPH)4-14 systems (using snapshots taken at 24 ps-
intervals from 8 independent restrained MD runs of 12 ns 
each). ΔGbind values for active sites A and B (containing pro-R 
poses) and those for active sites C and D (containing pro-S 
poses) are averaged and plotted in (Figure 5). 
For SR-1, ΔGbind values for pro-R and pro-S poses are high-
ly similar (left-hand side of Figure 5), indicating no particular 
preference for either prochirality in any of the enzyme vari-
ants. The only significant difference is that the P94L mutant 
indiscriminately shows a higher affinity for both orientations 
(more negative by ~1.5 kcal mol−1 with respect to WT and 
V151L actKR). More variation is observed between the bind-
ing energies for pro-R and pro-S poses of RS-1 (right-hand 
side of Figure 5). Whilst both orientations retain similar bind-
ing affinities in WT actKR (ΔΔGbind ≈ 0), this is clearly not the 
case in the two mutants: RS-1 in pro-R orientation has a signif-
icantly higher affinity (compared to its pro-S orientation) in 
both V151L actKR (ΔΔGbind = 1.9 kcal mol
−1) and P94L 
actKR (ΔΔGbind = 3.6 kcal mol
−1). This increase in ΔΔGbind 
when going from V151L to P94L actKR is mainly caused by a 
loss in affinity for the pro-S orientation. 
 
Figure 5.  Binding free energies (ΔGbind) predicted by MM/PBSA 
calculations on (left) SR-1; and (right) RS-1; either in pro-R poses 
(black or grey, respectively); or in pro-S poses (red or orange, 
respectively).  Observations for pro-R poses are averaged between 
monomers A and B; those for pro-S between C and D. See also 
color codes in Chart 1; lines are guides for the eyes. Error bars 
correspond to the standard error of the mean. 
In the case of WT actKR, enantiomers of 1 all have similar 
binding affinities regardless of orientation (with a slight pref-
erence of SR-1 in either pose over RS-1, ΔΔGbind ≈ 0.75 kcal 
mol–1). In the case of V151L, only the pro-R RS-1 pose has 
significantly higher affinity, with pro-S RS-1 at the same level 
as both SR-1 orientations (in line with the preferential for-
mation of reactive poses for pro-R RS-1, vide supra). For 
P94L, there is a significant loss in affinity of pro-S RS-1 (or-
ange), whereas pro-R RS-1 and both SR-1 poses have similar 
affinities (within 1 kcal mol−1). Based on the stereoselectivity 
observed in vitro,14, 16-17 one might expect to see a greater 
(more negative) binding affinity of pro-S poses for at least one 
of SR-1 / RS-1 (red / orange) in the case of P94L (as well as a 
greater binding affinity of pro-R poses in at least one of SR-1 / 
RS-1 in the case of V151L, as is observed here). Thus, FII is 
not likely to be involved in determining the stereoselectivity of 
P94L actKR, but may contribute instead to that of V151L 
actKR.  
Free Energy Barrier of Reaction: FIII.  To probe the ef-
fects of FIII on the stereoselectivity of WT actKR and its 
mutants, we have used QM/MM MD umbrella sampling simu-
lations to obtain free energy profiles for each of the four pos-
sible reductions of trans-1-decalone to trans-1-decalol (1 to 2, 
Figure 6). Profiles have been normalized so that the free ener-
gy of 1 on the “reactants” side is equal to zero, and each plot 
has been color-coded according to the stereoisomer of 2 ob-
tained (cf. color codes in Chart 1). Note that the unusually 
high energy barriers and reaction energies are mainly due to 
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the use of PM6 for the QM region (see Supporting Infor-
mation, Figure S2); in addition, the small QM region, the ap-
proximate reaction coordinate and, in case of reaction ener-
gies, the fact that we do not sample subsequent proton trans-
fers,15 will likely contribute to overestimation. We note that 
differences in reaction barrier height are what is relevant for 
investigation of the influence of FIII on stereoselectivity.  
 
Figure 6. Free energy profiles resulting from QM/MM MD US 
simulations (PM6/ff14SB) of the conversion of 1 to 2 in: (left) 
P94L actKR; (center) V151L actKR; and (right) WT actKR.  In 
each panel, each curve is the cumulative result of 10 individual 
simulations run for the 4 possible combinations of: SR-1 or RS-1 
(darker- vs. lighter-colored curves); and final R-2 or S-2 
stereochemistry (black/grey vs. red/orange, respectively; cf. Chart 
1). Regions close to the transition state (blue dotted line) are 
magnified in the blue insets, with error bars; errors are obtained 
through Monte-Carlo bootstrapping (see Supporting Information 
for details). 
For P94L actKR (Figure 6, left panel), SSR-2 (red) is indi-
cated as the most easily accessible stereoisomer of 2, through 
a free energy barrier that is at least 5 kcal mol−1 lower than 
those required to access either R-2 stereoisomer, and about 4 
kcal mol−1 lower than that required for the formation of SRS-2. 
This finding is in line with the S-specificity detected in vitro,16 
and is further substantiated by the fact that reaching either of 
the two R-2 stereoisomers (black and grey) is far more diffi-
cult in this variant than in either V151L or WT actKR. The 
fact that the barrier to reach the other S-2 stereoisomer (SRS-2; 
orange) is also higher than in the other forms of actKR—
together with the aforementioned lower binding affinity for the 
pro-S RS-1 reactive pose (Figure 5)—suggests that S-2 selec-
tivity in P94L actKR is likely to arise from formation of SSR-2 
from SR-1. 
Findings for V151L (Figure 6, center panel) are less clear: 
although barriers to reach the two R-2 stereoisomers are in-
deed significantly lower than in P94L and WT actKR, barriers 
to reach the S-2 stereoisomers are both even lower, with for-
mation of SRS-2 exhibiting the lowest free energy barrier out 
of all investigated combinations. Taken on its own, this con-
tradicts the in vitro observation (specificity towards R-3 vs. S-
3):17 other factors are thus likely to play a more dominant role 
(vide infra). 
For WT actKR (Figure 6, right panel), a slightly lower free 
energy barrier is only detected for the conversion of RS-1 to 
SRS-2 (orange; 2.1 to 3.6 kcal mol−1 lower than the other 
three). None of the other three conversions stand out for being 
particularly “easier”. This may agree with only a mild prefer-
ence for S-3 being observed experimentally.14, 16 Finally, we 
note that the reaction barriers for the expected preferred reac-
tions are similar between the three enzyme variants. This is 
consistent with experiment,4, 14, 17 considering our approximate 
reaction simulation approach: the P94L and V151L mutations 
only have very minor effects on the measured conversion rate 
(kcat) of racemic 1 to 2, which translate (using transition state 
theory) to subtle increases in the free energy of activation 
(ΔG‡) of 0.8 kcal mol−1 and 0.4 kcal mol−1, respectively. 
Different Factors Dominate for Different Variants. Taking 
into account the data for FI-FIII arising from our different 
simulations (Figure 4, Figure 5, and Figure 6), it becomes 
clear that the causes driving stereocontrol in each actKR vari-
ant are likely to be different.  
For V151L actKR, expected to have a strong R-preference, 
the RS-1 enantiomer is significantly more prone to form reac-
tive pro-R poses in the enzyme active site (FI). In addition, 
binding of reactive pro-R RS-1 poses is thermodynamically 
favored over the other possibilities (FII). It is true that reach-
ing RRS-2 from pro-R RS-1 is significantly easier in V151L 
actKR than in any of the other variants investigated (FIII; 
Figure 6), however, this in itself this would not enhance stere-
oselectivity, as barriers to other species are equally reduced. It 
therefore appears that for V151L actKR, stereoselectivity is 
mainly determined by the sterics and thermodynamics prior to 
the reduction step (FI and FII). As such, our calculations indi-
cate that this variant will predominantly form RRS-2 (instead 
of RSR-2). 
In the case of the WT enzyme, mild selectivity can be ex-
pected towards S-2 (based on its experimentally determined 
specificity towards S-3). The pro-S reactive poses are some-
what more easily attained within its active site (FI; Figure 4), 
with SR-1 being the best-placed enantiomer to reach its SSR-2 
product. Thus, for SSR-2 formation (compared to RSR-2), this 
“steric head start” is likely important. Formation of the other 
S-2 isomer, SRS-2, is favored by its lower free energy barrier 
(FIII; Figure 6). FII (Figure 5) appears to play no significant 
role for stereoselectivity. 
For P94L actKR, the situation is significantly different: its 
strong S-2 selectivity (as expected from its in vitro specificity 
towards S-3) mostly arises due to a change in relative reaction 
barriers (FIII). Specifically, formation of SSR-2 is clearly 
preferred (Figure 6). FI may play some additional role, since 
SR-1 forms more pro-S reactive poses. Altogether, the simula-
tions further indicate that this variant will predominantly form 
SSR-2 (instead of SRS-2): pro-S RS-1 reactive poses occur less 
frequently and have lower affinity than pro-S SR-1 reactive 
poses (Figure 4; Figure 5), and they are also much less favored 
to react to SRS-2 (FIII; Figure 6).   
Table 2. Key Structural Features of Reactive Poses of 1 
Enantiomer SR-1 SR-1 RS-1 RS-1 
Prochirality pro-R pro-S pro-R pro-S 
Non-CO ringa → 94 → 151 → 94 → 151 
H– in 2b Axial Equatorial Equatorial Axial 
a Approximate direction towards which 1’s C4a-C5-C6-C7-C8-
C8a ring points: P/L94 vs. V/L151. b Final position of the trans-




Figure 7. Representative snapshots of approximate transition states from QM/MM MD US simulations (obtained from clustering on the 
substrate RMSD after alignment on the cofactor). (a) pro-R RS-1 to RRS-2 in WT actKR; (b) pro-S SR-1 to SSR-2 in WT actKR; (c) pro-R 
RS-1 to RRS-2 in V151L actKR; and (d) pro-S SR-1 to SSR-2 in P94L actKR. In each case, snapshots are taken from the 0.2 simulation 
window; all four choices depict equatorial attack. Key and orientation: same as Figure 2; mutations in (c) and (d) are marked in magenta. 
Our extensive atomistic simulations allow investigation of 
geometrical characteristics within each active site that may 
help rationalize the above findings. Considering the orienta-
tion of RS-1 and SR-1 in the active site (Table 2); as well as 
representative transition states for their reaction to 2 (Figure 
7), it emerges that (pro)chiralities enhanced by each mutation 
(R for V151L; S for P94L) are those which do not entail a 
steric clash between the non-carbonyl ring of 1 and the extra 
bulk introduced by that mutation. We note that, in this case, 
this effect could not be reproduced by standard molecular 
docking (likely due to the active site’s large volume compared 
to 1). 
There appears to be a slight difference in the effect brought 
about by mutant sidechains. The L151 sidechain (Figure 7c) 
extends more directly into the active site, and thus influences 
prochirality by ‘stealing’ volume from prospective pro-S poses 
(from the side of the non-carbonyl ring), making such poses 
less likely (FI). The L94 sidechain appears to have a subtler 
effect (Figure 7d), potentially affecting the orientation of the 
substrate during reaction (thereby affecting FIII).  
Trans-1-decalone Enantiomers and Equatorial Attack. 
Our work indicates that P94L actKR prefers facilitating the 
reaction of pro-S SR-1, and V151L actKR prefers facilitating 
pro-R RS-1. A significant difference in SR-1 and RS-1 com-
plexes with actKR already emerged from investigation of FI 
(Figure 4), indicating a general preference of pro-S reactive 
poses with SR-1 (dark blue), and pro-R reactive poses with 
RS-1 (light blue), regardless of the actKR variant considered. 
These observations, in combination with the geometrical fea-
tures from the simulations (Table 2 and Figure 7), indicate that 
both enantiomers of 1 are prone to react in the prochirality that 
favors equatorial rather than axial hydride attack. This con-
trasts with previous literature on the non-enzymatic reduction 
of 1 in vitro71-72 (with reagents such as [BH4]
– and [AlH4]
–), 
which shows that the favored product is instead the one result-
ing from axial attack. A similar preference for the axial prod-
uct was found computationally for the non-enzymatic reduc-
tion of cyclohexanone,72 with the transition state for axial at-
tack found to be about 1.8 kcal mol–1 more stable.  
The preference we predict for equatorial hydride attack in 
the enzymatic reduction by actKR is, however, entirely in line 
with experimental findings by Østergaard et al.,73 which 
showed SR-1 (from a racemate of 1) to preferentially undergo 
equatorial attack (to form SSR-2) within the ketoreductase 
module of the erythromycin polyketide synthase. The authors 
further concluded that, in the reverse direction, the enzyme 
preferentially turns over a racemate of RRS-2 and SSR-2 (as 
opposed to one of RSR-2 and SRS-2) 
Does Selectivity for Trans-1-decalone Reduction Equal 
Specificity for α-tetralol Oxidation? The significant differ-
ence between actKR complexes with RS-1 and SR-1 prompts a 
deeper discussion on the general assumption that selectivity 
towards trans-1-decalone and α-tetralone are directly compa-
rable. Resolving the stereochemical outcome of the “forwards” 
reaction with trans-1-decalone (by assessing S-2 : R-2 ratio) 
was not successful, despite trying several approaches (person-
al communication with Prof. SC Tsai, UC Irvine). Korman, 
Javidpour et al.14, 16-17 thus investigate specificity in the reverse 
reaction for S-3 and R-3 (commercially available, unlike the 
stereoisomers of 2); studying the “forwards” reduction of α-
tetralone is hampered by actKR’s very sluggish turnover of 
that substrate.  
To obtain detailed insight into (the stereoselectivity of) re-
duction of trans-1-decalone, which is readily turned over by 
the three enzyme variants studied here (Table 1), we opted to 
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investigate the “forwards” reaction (reduction of 1 to 2). Note 
that had we chosen to study the reaction using α-tetralone/3 
instead, a complication would have arisen because the aliphat-
ic carbonyl ring can chair-flip freely (due to aromaticity in its 
non-carbonyl ring): chair-flipping—virtually unachievable in 
1—would have introduced a considerable degree of complexi-
ty in our simulations. We thus rely on the assumption (also 
made by Korman, Javidpour et al.)14, 16-17 that the reduction of 
1 to (R/S)-2 remains (through a degree of microscopic reversi-
bility) comparable to the oxidation of (R/S)-3 to α-tetralone. 
(This issue is reminiscent of the “experimental problem” re-
viewed by Van Gunsteren and colleagues,74 whereby experi-
mental data is sometimes scarcer than desirable when setting 
up biomolecular simulations). We believe this assumption to 
be reasonable in this case, because in each of the two ‘chair-
flip’ conformers of α-tetralone, the carbonyl and three aliphat-
ic carbons are likely to have a near-identical arrangement to 
atoms C1-C4 (Chart 1) in RS-1 or SR-1 (there would be the 
same such correspondence between S-3 and SSR-2/SRS-2; and 
between R-3 and RSR-2/RRS-2). The only major (steric) dif-
ference would be the axial atoms in 1 and 2 jutting out above 
and below the plane of the non-carbonyl ring: as a result, we 
speculate that the 1/2 pair could be more susceptible to steric 
hindrance at its non-reactive (non-carbonyl) end, possibly 
increasing the degree of stereoselectivity towards 1 compared 
to α-tetralone/3. 
Towards an Efficient Approach for Understanding Enzy-
matic Stereocontrol. The procedure that we employ in this 
study relies on carefully chosen computational methods to 
dissect the influence of FI-FIII—something that is very hard 
to achieve experimentally. We have deliberately used proto-
cols that (1) require input of the WT structure only; (2) use 
relatively limited computational resources (short simulations 
and semiempirical QM treatment); and (3) can be automated. 
We thus envisage that these protocols can be used in a way 
that is conceptually similar to the ‘high‐throughput–multiple 
independent MD simulations’ (HTMI-MD) approach used by 
Wijma and coworkers24, 75-76 to efficiently screen newly sug-
gested stereoselective enzyme variants in silico, prior to as-
sessment by experiment. We note that the HTMI-MD ap-
proach only assesses FI, whereas we have shown here that, in 
particular, FIII can be crucial to understand stereoselectivity 
in certain ketoreductase variants (P94L actKR).  
The protocols serve to obtain prediction of and insight into 
stereoselectivity in novel mutants relatively rapidly, and could 
thus aid the design of novel mutants. For the use of such tools 
to become more widespread, and to allow screening a large 
number of enzyme variants, the computational time and re-
sources required should be modest. In this respect, the fact that 
our relatively low-cost protocols have been able to character-
ize the stereoselectivity of WT, P94L and V151L actKR with 
encouraging matches to experimental data shows promise for 
future applications to other enzymes and mutants. In this sub-
section, we discuss the rationale for the protocols to assess FI-
FIII and evaluate if computational time can be reduced fur-
ther.  
To study FI (and to later generate trajectories for FII and 
FIII) we employed classical MD simulations, previously em-
ployed in several examples of interest with other KRs and 
SDRs.10, 77 In contrast to many previous studies that have used 
a small number of longer MD simulations to collect their da-
ta,10, 26, 77-78 our strategy was to run a large set of independent 
MD simulations of shorter length (8 × 12 ns, essentially be-
coming 32 × 12 ns due to the four active sites) to maximize 
conformational sampling. This length is still significantly 
greater than those employed by Wijma et al. (20-40 × 10 ps or 
10 × 100 ps),24, 76 because this may be necessary to capture 
relevant enzyme conformational changes. The importance of 
carrying out multiple independent MD replicas (at least 5-10 
as a rule-of-thumb) has been recently restated.79 
In the case of ketoreductases/SDRs, the α6-α7 loop can 
adopt alternative conformations (Figure 1c and d), and was 
proposed to play a role in determining reactivity and selectivi-
ty in a different enzyme.10 We thus confirmed (vide infra) that 
the 12 ns simulation length is sufficient for “closed” chains (B, 
D) to sample open α6-α7 loop conformations and vice versa 
for “open” chains (A, C). We further explored the possibility 
of investigating FI with simulations shorter than 12 ns, and 
our data (Supporting Information, Figure S4) show that this is 
feasible: trends are identical with simulations shorter than 0.3 
ns, leaving the conclusions unaltered. 
The MM/PBSA option was chosen to study FII in light of 
its relatively modest computational cost, as well as its good 
performance in previous ΔGbind-prediction problems across 
several enzyme-ligand systems.32, 80-81 Alternative options such 
as absolute binding free energy calculations using alchemical 
perturbations30-31 would have raised the computational cost 
significantly.82 Our decision to run MM/PBSA calculations on 
a large set of independent MD simulations was to maximize 
conformational sampling, and has been shown to improve 
performance.83-84 In fact, though in our case we employed 12 
ns MD replicas to adequately sample conformational changes 
in the α6-α7 loop, previous work shows that much shorter MD 
simulations (in the order of hundreds of ps to a few ns) are 
typically sufficient.83-84 In our case, tests suggest that using 
MD trajectories shorter than 4-8 ns may have repercussions on 
accuracy (Supporting Information, Figure S5); likely in part 
due to the use of fewer snapshots overall. (The 24 ps-interval 
at which snapshots are extracted is roughly in line with previ-
ous MM/PBSA and MM/GBSA indications, but could be re-
duced).83-85  
To study FIII, we employed a semiempirical QM/MM ap-
proach, to avoid specific parameterization of models (e.g. as 
required for empirical valence bond methods)36 and limit com-
putational cost (e.g. as compared to QM/MM or a QM cluster 
approach with DFT methods). To further limit this cost, we 
chose to use a small QM region with only groups directly elec-
tronically involved in the rate-limiting step (Figure 3), rather 
than a region that incorporates possible further proton transfers 
(as used in previous QM/MM studies of actKR-related en-
zymes).10, 15 A wide range of options is available for calculat-
ing reaction barriers with QM/MM.37-38 In our case, it was not 
known a priori what the orientation of the substrate would be 
in the different variants (due to its small size in comparison to 
the relatively large active site in actKR). Therefore, an ap-
proach using QM/MM optimization alone was not ideal, since 
both the initial choice of substrate orientation and enzyme 
conformation may have a large influence on the resulting acti-
vation energy barriers, and this would have meant collecting a 
very large number of starting conformations.86 We thus opted 
for QM/MM MD reaction simulations to allow sampling of 
many orientations, as well as full consideration of entropic 
effects. Conformational sampling was further enhanced by 
performing 10 independent reaction simulations (leading to 20 
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ps sampling per umbrella sampling window), for each of the 
four possible reactions, across the three actKR variants (120 in 
total); indeed, our tests with 36 independent simulations (3 per 
case, 6 ps per window; Supporting Information, Figure S6) 
show that results become significantly less reliable (with larg-
er errors).  
Notably, QM/MM simulations used a range of starting 
structures from the many independent classical MD simula-
tions performed: these capture a range of α6-α7 loop confor-
mations (between ‘open’ and ‘closed’). As mentioned earlier, 
in contrast to previous work on Lactobacillus kefir short-chain 
alcohol dehydrogenase,10 we found little correlation between 
the loop openness (as measured by the average of three intera-
tomic loop-enzyme distances) and barrier height (Supporting 
Information, Figures S7 and S8), indicating that in this case, 
that the α6-α7 loop conformation has little or no influence on 




Biocatalyst (stereo)selectivity can arise due to a combina-
tion of effects, including substrate binding (and its affinity in 
different orientations), as well as reaction barrier. Such effects, 
and their interplay, can be subtle, especially when dealing with 
a relatively open active site (as in the case of actKR, the en-
zyme studied here). One route towards stereoselective en-
zymes (for use in biocatalysis) can thus be to reduce their ac-
tive site volume (e.g. in such a way that substrates can only 
bind in specific orientations).24, 78 However, such changes may 
also reduce their capability for turning over a range of sub-
strates (of different sizes) as well as reduce efficiency. 
Here, we have presented a detailed computational study of 
three factors that may affect stereocontrol in the wild-type 
ketoreductase actKR and in two key variants with similar effi-
ciency (P94L, V151L). We separately investigated the for-
mation (FI), the binding free energy (FII) and the reactivity 
(free energy barrier, FIII) of reactive complexes, using classi-
cal MD simulations, MM/PBSA calculations and QM/MM 
MD reaction simulations, respectively. We demonstrate that 
the strict stereoselectivity observed in the P94L and V151L 
actKR variants (both leading to only a small decrease in active 
site volume) is arising through different mechanisms in each 
case. For the S-selective P94L actKR variant, stereoselectivity 
is driven by the relative difference between activation free 
energy barriers (FIII), whereas for the R-selective V151L 
actKR variant, the formation and binding affinity of reactive 
substrate poses (FI, FII) are mainly responsible. 
The observation that the main effect (or factor) determining 
stereocontrol can differ from mutant to mutant has important 
implications for obtaining stereoselective enzymes through 
redesign: either substrate orientation or efficiency of catalysis 
(via transition state stabilization), or both, may be either al-
tered to confer stereoselectivity. 
Our simulations further indicate that each enantiomer of the 
substrate trans-1-decalone (1) has a preference for particular 
reactive poses: pro-S poses are predominantly found for SR-1, 
and pro-R poses for RS-1. We note that this was observed in 
all three actKR variants studied, including the mildly S-
selective WT actKR. For the stereoselective reduction of 1, it 
is thus the combined effects of the actKR variant and substrate 
enantiomer that determine the final product, with P94L favor-
ing formation of SSR-2 and V151L favoring formation of 
RRS-2. 
The complexity of our findings is representative of the mul-
tifaceted origins of catalysis and selectivity in enzyme biocata-
lysts, which arises from a subtle interplay of steric, dynamic, 
and electronic effects. Detailed biomolecular simulation pro-
vides valuable means to break down the causes of stereocon-
trol (e.g. in terms of the individual factors FI-FIII). The com-
putational procedures we have used here to determine the ori-
gins of stereocontrol in actKR are deliberately generically 
applicable and employ limited computer resources. They can 
thus be used for similar evaluations of different enzyme bio-
catalysts in a time- and cost-effective manner (especially in 
combination with further automation); although it should be 
noted that evaluation of FIII does require the reaction mecha-
nism to be known in advance. Indeed, we believe that an accu-
rate, yet computationally efficient assessment of the different 
effects (or factors) dictating an enzyme’s stereocontrol is high-
ly valuable for the (re)design of biocatalysts with enhanced 
stereoselectivity or -specificity, as well as for in-depth under-
standing of selectivity in existing enzyme variants.  
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